Please login to the form below

Not currently logged in
Email:
Password:

TauRx

This page shows the latest TauRx news and features for those working in and with pharma, biotech and healthcare.

Another amyloid bust as Roche pulls crenezumab trials

Another amyloid bust as Roche pulls crenezumab trials

AD have also yielded disappointing results for companies including TauRx, Zeltia, Bristol-Myers Squibb and Allon/Paladin Labs.

Latest news

  • Lilly partners with AC Immune on tau drug for Alzheimer’s Lilly partners with AC Immune on tau drug for Alzheimer’s

    The company credited with pioneering the tau hypothesis in AD is TauRx, although its aggregation inhibitor LMTX disappointed in an 891-paient phase 3 trial reported in 2016.

  • AbbVie takes anti-tau drug into phase II for Alzheimer's AbbVie takes anti-tau drug into phase II for Alzheimer's

    Whether tau-targeting drugs can do better remains to be seen. Last year, TauRx's tau aggregation inhibitor LMTX failed to slow cognitive decline in three phase III trials - two in ... TauRx also said it had cognitive benefit in a subset of patients not

  • Tau protein drug fails late-stage trial Tau protein drug fails late-stage trial

    year. TauRx' tau aggregation inhibitor LMTX failed to meet its objective of improving cognition and the ability to carry out everyday tasks in the trial, which involved 891 patients with mild ... TauRx has two other trials in play – one in mild

  • AbbVie and C2N take tau antibody into clinic AbbVie and C2N take tau antibody into clinic

    Other companies working on tau as a target include TauRx Therapeutics, which has a phase III trial ongoing of its lead candidate LTX in Alzheimer's and is due to report

  • Alzheimer's disease pipeline takes multiple hits Alzheimer's disease pipeline takes multiple hits

    Of these, TRx 0237 (leuco-methylthioninium, TauRx Pharmaceuticals), an oral agent shown to inhibit tau aggregation, is in phase III trials in the US and the UK in patients with ... Two agents targeting tau have been discontinued recently at phase II –

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics